Pfizer raises pressure on GSK, J&J with late-stage RSV vaccine trialPfizer has vaulted ahead with its respiratory syncytial virus (RSV) vaccine, closing the gap with GlaxoSmithKline and Johnson Share XPfizer raises pressure on GSK, J&J with late-stage RSV vaccine trialhttps://pharmaphorum.com/news/pfizer-raises-pressure-on-gsk-jj-with-late-stage-rsv-vaccine-trial/
Merck & Co raises pressure on Pfizer in pneumococcal vaccine tussleJust a month after getting approval for its new pneumococcal vaccine Vaxneuvance in adults, Merck & Co has Share XMerck & Co raises pressure on Pfizer in pneumococcal vaccine tusslehttps://pharmaphorum.com/news/merck-raises-pressure-on-pfizer-in-pneumococcal-vaccine-tussle/
Sanofi swoops on partner Translate, buying the mRNA firm for $3.2bnSanofi has been forging ever-closer ties with its mRNA partner Translate Bio since the two started working together Share XSanofi swoops on partner Translate, buying the mRNA firm for $3.2bnhttps://pharmaphorum.com/news/sanofi-swoops-on-partner-translate-buying-the-mrna-firm-for-3-2bn/
Takeda spins norovirus vaccine out into separate companyTakeda has decided development of its norovirus vaccine candidate outside Japan will be more efficient if it is Share XTakeda spins norovirus vaccine out into separate companyhttps://pharmaphorum.com/news/takeda-spins-norovirus-vaccine-out-into-separate-company/
Shot in the arm for Affinivax as it challenges Pfizer’s PrevnarAlready facing one rival to its blockbuster pneumococcal vaccine Prevnar, Pfizer could have another to contend with, after Share XShot in the arm for Affinivax as it challenges Pfizer’s Prevnarhttps://pharmaphorum.com/news/shot-in-the-arm-for-affinivax-as-it-challenges-pfizers-prevnar/
Moderna plans triple vaccine targeting flu, COVID and RSVBuoyed by the success of its COVID-19 vaccine, Moderna has started a phase 1/2 trials of its mRNA-based Share XModerna plans triple vaccine targeting flu, COVID and RSVhttps://pharmaphorum.com/news/moderna-plans-triple-vaccine-targeting-flu-covid-and-rsv/
COVID-19 vaccine development: Safety monitoring continues revolution in RWDFrom cancer to COVID, real-world data is changing the way we research therapeutics, monitor safety, and collaborate on Share XCOVID-19 vaccine development: Safety monitoring continues revolution in RWDhttps://pharmaphorum.com/r-d/covid-19-vaccine-development-safety-monitoring-continue-the-revolution-in-real-world-data/
Sanofi doubles down on mRNA jabs with €400m-a-year R&D driveSanofi has just significantly increased its investment in mRNA vaccine development, earmarking €400 million ($475 million) a year Share XSanofi doubles down on mRNA jabs with €400m-a-year R&D drivehttps://pharmaphorum.com/news/sanofi-doubles-down-on-mrna-jabs-with-e400m-yearly-rd-drive/
AZ, Sanofi prep filings for one-shot RSV antibody after trial winAstraZeneca and Sanofi now have the data they need in hand to press ahead with regulatory filings next Share XAZ, Sanofi prep filings for one-shot RSV antibody after trial winhttps://pharmaphorum.com/news/az-sanofi-prep-filings-for-one-shot-rsv-antibody-after-trial-win/
